INTERNATIONAL JOURNAL OF ONCOLOGY 38: 629-641, 2011 High EGFR mrna expression is prognostic fctor for reduced survivl in pncretic cncer fter gemcitbine-bsed djuvnt chemotherpy Hyto Fujit 1, Kenoki Ohuchid 1,2, Kzuhiro Mizumoto 1,3, Soichi Itb 4, Tetsuhide Ito 4, Kohei Nkt 1,5, Jun Yu 1, Tdshi Kyshim 1, Akifumi Hyshi 1,5, Ryot Souzki 6, Ttsuro Tjiri 6, Mnbu Onimru 1, Ttsuy Mnbe 1, Tko Ohtsuk 1 nd Mso Tnk 1 Deprtments of 1 Surgery nd Oncology, nd 2 Advnced Medicl Inititives, Grdute School of Medicl Sciences, Kyushu University; 3 Kyushu University Hospitl Cncer Center, 3-1-1 Midshi; Deprtments of 4 Medicine nd Bioregultory Science, 5 Antomic Pthology, nd 6 Peditric Surgery, Grdute School of Medicl Sciences, Kyushu University, 3-1-1 Midshi, Fukuok 812-8582, Jpn Received October 26, 2010; Accepted December 20, 2010 DOI: 10.3892/ijo.2011.908 Abstrct. Pncretic ductl denocrcinom (PDAC) still presents mjor therpeutic chllenge nd phse III clinicl tril hs reveled tht the combintion of gemcitbine nd humn epiderml growth fctor receptor type I (HER1/ EGFR) trgeting gent presented significnt benefit compred to tretment with gemcitbine lone. The im of this study ws to investigte EGFR mrna expression in resected PDAC tissues nd its correltion with ptient prognosis. We obtined formlin-fixed prffin-embedded (FFPE) tissue smples from 88 ptients with PDAC who underwent pncretectomy, nd mesured EGFR mrna levels by quntittive rel-time reverse trnscription-polymerse chin rection. The highlevel EGFR group hd significntly shorter disese-free-survivl (p=0.029) nd overll-survivl (p=0.014) s shown by univrite nlyses, lthough these did not rech sttisticl significnce, s shown by multivrite nlyses. However, we found tht high EGFR expression ws n independent prognostic fctor in ptients receiving gemcitbine-bsed djuvnt chemotherpy (p=0.023). Furthermore, we mesured Correspondence to: Dr Kenoki Ohuchid or Dr Kzuhiro Mizumoto, Deprtment of Surgery nd Oncology, Grdute School of Medicl Sciences, Kyushu University, 3-1-1 Midshi, Fukuok 812-8582, Jpn E-mil: kenoki@med.kyushu-u.c.jp E-mil: mizumoto@med.kyushu-u.c.jp Key words: epiderml growth fctor receptor, pncretic cncer, reverse trnscription-polymerse chin rection, formlin-fixed prffin-embedded smples, endoscopic ultrsound-guided fine needle spirtion EGFR mrna levels in 20 endoscopic ultrsound-guided fine needle spirtion (EUS-FNA) cytologicl specimens. Altered EGFR levels were distinguishble in microdissected neoplstic cells from EUS-FNA cytologicl specimens compred to those in whole cell pellets. In conclusion, quntittive nlysis of EGFR mrna expression using FFPE tissue smples nd microdissected neoplstic cells from EUS-FNA cytologicl specimens could be useful in predicting prognosis nd sensitivity to gemcitbine in PDAC ptients. Introduction Pncretic ductl denocrcinom (PDAC) is one of the most lethl nd ggressive humn mlignncies, nd it is the fourth leding cuse of tumor-relted deths in the industrilized world (1,2). The vst mjority of ptients with PDAC hve poor outcomes due to the ggressive nture of the tumor nd difficulties in erly dignosis due to the lck of erly disesespecific signs nd symptoms. Only 10-20% of ptients with PDAC hve chnce of curtive resection (3) nd, even if the curtive resection is performed, the post-opertive 5-yer survivl rte is only 15-25% due to high recurrence rte (4,5). Two rndomized clinicl phse III trils of djuvnt chemotherpy (AC) for PDAC hve shown significnt increses in overll survivl (OS) nd disese-free survivl (DFS). However, their efficcy ws limited nd insufficient (6,7). To improve the prognosis of ptients with PDAC, individulized chemotherpy bsed on the gene expression profiles of the individul's own cncer tissues, could be potent strtegy. Humn epiderml growth fctor receptor type 1 (HER1/ EGFR) is receptor tyrosine kinse. Binding of lignd growth fctors, such s epiderml growth fctor (EGF) nd trnsforming growth fctor (TGF)-α to EGFR leds to receptor phosphoryltion nd ctivtion of downstrem Rs/mitogenctivted protein kinse (MAPK) signling, thereby enhncing the mlignnt behvior of cncer cells (8,9). There is incresing
630 fujit et l: EGFR mrna expression in PDAC evidence showing tht the dysregultion of EGFR pthwys by overexpression or constitutive ctivtion cn promote tumor growth nd metstsis, nd tht this is ssocited with poor prognosis nd tumor ggressiveness in mny humn mlignncies, including pncretic cncer (10-13). To improve the prognosis of PDAC ptients, the blockde of the EGFR signling pthwy could be potent strtegy (9,14). The EGFR signling blockde hs been reported to decrese growth nd metstsis in n orthotopic implnttion murine model of pncretic cncer cells (15) nd to improve the efficcy of gemcitbine in humn pncretic tumor xenogrft models (16). At the time of dignosis, >80% of PDAC ptients present with either loclly dvnced or metsttic disese (3). Therefore, ptients with unresectble dvnced PDAC require cytopthologicl ssessment using endoscopic ultrsoundguided fine needle spirtion (EUS-FNA) or pncretic juice specimens to predict their sensitivity to chemotherpeutic gents nd prognosis. Quntittive mrna nlysis of genes ssocited with sensitivity to chemotherpeutic gents, or with ptient prognosis could be suitble for clinicl use s this method enbles us to reproducibly detect gene expression, even with smll smples (17). In the current study, we investigted the correltion between EGFR expression nd the prognosis of ptients with PDAC. To elucidte the role of EGFR expression in gemcitbine sensitivity, we lso investigted the ssocition between receptor expression levels nd tretment outcomes in PDAC ptients receiving gemcitbinebsed AC. Furthermore, we quntified EGFR expression in cytologicl specimens obtined by EUS-FNA to exmine the possible utility of such smples for quntifying the mrna levels of these predictive fctors. Mterils nd methods Ptients nd pncretic tissues. Our study subjects comprised of 88 ptients who underwent pncretectomy for PDAC t the Deprtment of Surgery nd Oncology, Kyushu University Hospitl (Fukuok, Jpn) from 1992 to 2007. The ptients (54 mle nd 34 femle) hd medin ge of 65 yers (rnge, 36-86 yers). Eighteen of the 88 ptients received no AC (non-ac group). Thirty-six of the 88 ptients received gemcitbine-bsed AC (GEM group), consisting of two or more cycles of 1,000 mg/m 2 /d gemcitbine on dys 1, 8 nd 15 every 28 dys, nd three or more cycles of 1,000 mg/m 2 /d gemcitbine on dys 1 nd 8 every 21 dys. Nineteen of the 88 ptients received other forms of AC (other AC group), including 5 ptients orlly dministered S-1 (80-100 mg/ body), 7 ptients orlly dministered tegfur (400-800 mg/ body), nd 7 ptients treted with bolus of 5-fluorourcil (250-500 mg/body). The remining 15 ptients did not receive dequte AC due to their poor performnce sttus. We recommended tht ptients hd follow-up visits every 3 months for 2 yers, then visits every 6 months for 3 yers, nd then nnul visits. DFS ws defined s the time from the dte of pncretic resection to the dte of locl or distnt recurrence. The dte of recurrence ws defined s the dte of the first subjective symptom herlding relpse, or the dte of documenttion of recurrent disese, independent of site, s ssessed by dignostic imging techniques (whichever occurred first). Dt for Tble I. Clinicopthologicl chrcteristics of the ptients (n=88). Medin ge 65 yers (rnge, 36 86 yers) Gender (mle/femle) 54 (61.4%)/34 (38.6%) Histologicl dignosis Adenocrcinom 86 (97.7%) Adenosqumous crcinom 2 (2.3%) Adjuvnt chemotherpy (AC) No 18 (20.5%) Yes 55 (62.5%) Gemcitbine-bsed AC 36 (40.9%) Other AC 19 (21.6%) Rdiotherpy including IOR Yes 23 (26.1%) No 53 (60.2%) pt ctegory pt1 5 (5.8%) pt2 3 (3.4%) pt3 78 (89.7%) pt4 1 (1.1%) pn ctegory pn0 27 (31.0%) pn1 60 (69.0%) UICC stge I 6 (6.9%) II 78 (89.7%) III 1 (1.1%) IV 2 (2.3%) Histologicl grde G1 20 (23.3%) G2 33 (38.4%) G3 33 (38.4%) Residul tumor ctegory R0 55 (63.9%) R1 31 (36.1%) Vessel invsion Positive 55 (63.2%) Negtive 32 (36.8%) Neurl invsion Positive 72 (82.8%) Negtive 15 (17.2%) ptients without recurrence were censored t the time of the lst follow-up visit. OS ws mesured from the dte of pncretic resection to the dte of deth. Fifty-eight ptients died during follow-up nd the other ptients were censored t the time of the lst follow-up visit. Dt were nlyzed in December 2009 nd follow-up dt from ll cses were vilble. The medin observtion time for DFS ws 9 months (rnge, 0.5-114 months) nd OS ws 18 months (rnge, 0.5-114 months). The clinicopthologicl chrcteristics of the tumors collected from 88 ptients re provided in Tble I. Additionlly,
INTERNATIONAL JOURNAL OF ONCOLOGY 38: 629-641, 2011 631 in order to compre the EGFR expression levels in PDAC tissues to those in non-mlignnt pncretic specimens, totl of 40 non-mlignnt pncretic tissues, including 10 norml pncretic tissues resected with bile duct crcinom nd 30 chronic pncretitis tissues, were lso obtined. All resected specimens were fixed in formlin nd embedded in prffin, nd ll tissues djcent to the specimens were evluted histologiclly ccording to the criteri of the World Helth Orgniztion. Two pthologists were in greement s regrds the pthologicl fetures of ll cses nd the dignoses were confirmed. The tumor stge ws ssessed ccording to the Union Interntionle Contre le Cncer (UICC) nd the Americn Joint Committee on Cncer guidelines (18). The study ws pproved by the Ethics Committee of Kyushu University nd conducted ccording to the Ethicl Guidelines for Humn Genome/Gene Reserch encted by the Jpnese Government nd the Helsinki Declrtion. Immunohistochemistry. A totl of 25 sections (4-µm thick) from formlin-fixed prffin-embedded (FFPE) specimens from 88 ptients with PDAC nd 15 sections from 40 nonmlignnt cses, including seven sections from norml pncres resected with bile duct crcinom, nd 8 sections from chronic pncretitis ptients, were deprffinized in xylene nd hydrted in grded ethnol. Endogenous peroxidse ctivity ws blocked by incubtion with 3% hydrogen peroxide in methnol for 30 min. Antigen retrievl ws chieved by utoclving the sections in citrte buffer t ph 6.0. The Histofine SAB-PO(R) kit (Nichirei, Tokyo, Jpn) ws used for immunohistochemicl lbeling. The sections were incubted with 1.5% norml got serum/phosphte-buffered sline, followed by incubtion with rbbit polyclonl nti- EGFR ntibody (Snt Cruz Biotechnology, Snt Cruz, CA) t 1:50 dilution overnight t 4 C. The sections were incubted with biotinylted nti-rbbit immunoglobulin solution for 20 min followed by peroxidse-lbeled streptvidin for 20 min. Immunocomplexes were visulized using stble 3,3'- diminobenzidine tetrhydrochloride (Dojin, Kummoto, Jpn). The sections were rinsed with distilled wter nd counterstined with hemtoxylin for 10 sec. The mount of EGFR immunorectivity ws evluted using the following scle ccording to the percentge of EGFR-positive cncer cells: 0, <5%; 1, 5 25%; 2, 26 50%; nd 3, >51%. Stining intensity ws scored semi-quntittively s follows: 0, bsent; 1, wek; 2, moderte; 3, strong. To perform the quntittive nlysis of EGFR immunorectivity, the following combined score ws determined: Degree of stining = quntity x intensity. We lso performed dditionl stining without primry ntibodies s the negtive control. All slides were evluted independently by three investigtors (H.F., A.H. nd K.N.) without ny knowledge of the bckground of ech cse. Cytologicl specimens. Cytologicl specimens were obtined t the time of cytologicl exmintion nd dignosis from the pthologicl lbortory of Kyushu University Hospitl. In brief, cytologicl specimens were divided into whole cell pellets (WCP) nd into three or more smers s soon s possible fter retrievl. Smers were processed in three different wys s described previously (17). Two smers were mounted on stndrd glss slides for Hemcolor stining (Merck KGA, Drmstdt, Germny) nd Ppnicolou stining, then used for rpid cytologicl dignosis nd strict cytologicl dignosis, respectively. These two smers were exmined histologiclly by cytopthologists nd dignosis ws confirmed ccording to the Ppnicolou Clssifiction. The third smer of ech specimen ws mounted on membrne slides (Leic Microsystems, Wetzlr, Germny) for lser cpture microdissection (LCM). These smers were stined in 1% toluidine blue stining solution or by Hemcolor stining. Twenty cytologicl specimens were obtined from ptients t the Kyushu University Hospitl who underwent EUS-FNA cytology nd who were cytopthologiclly dignosed with PDAC. Isoltion of RNA. Totl RNA ws isolted from FFPE tissue smples using the RNesy FFPE kit (Qigen, Tokyo, Jpn) with some modifiction to the mnufcturer's instructions fter mcrodissection bsed on review of representtive hemtoxylin nd eosin-stined slides s described previously (19). Totl RNA ws extrcted from cells isolted by microdissection ccording to the stndrd cid gunidinium thiocynte-phenol-chloroform protocol (20), with or without glycogen (Funkoshi, Tokyo, Jpn). Quntittive rel-time reverse trnscription-polymerse chin rection (qrt-pcr). qrt-pcr ws performed using the Chromo4 Rel-Time PCR Detection System (Bio-Rd Lbortories, Hercules, CA, USA) nd the LightCycler 480 II Rel-Time PCR System (Roche Dignostics) for 40 cycles of 15 sec t 95 C nd 1 min t 55 C with the QuntiTect SYBR- Green Reverse Trnscription-PCR kit (Qigen) in ccordnce with the mnufcturer's instructions (21). We designed specific primers for EGFR (forwrd primer, 5'-ccttgtgcggg tttgtcttt-3'; nd reverse primer, 5'-ccctgtgttggggctg-3') nd β-ctin (forwrd primer, 5'-tggcgcggctcgctt-3'; nd reverse primer, 5'-tcctttgtccgccgttt-3'), nd screened dtbse using BLASTN to confirm the primer specificities. The level of ech mrna ws clculted from stndrd curve constructed using totl RNA from Cpn-1, humn pncretic cncer cell line. The level of EGFR mrna ws normlized to tht of β-ctin. The PCR product sizes of EGFR nd β-ctin primers were smll [88 bse pirs (bp) nd 59 bp, respectively], which llowed for ccurte nd sensitive qrt-pcr nlysis despite the frgmented RNA extrcted from the FFPE tissue specimens (22,23). Sttisticl nlyses. Sttisticl nlyses nd grphicl presenttions were performed using JMP 7.01 softwre (SAS Institute, Cry, NC, USA). Vlues were expressed s the mens ± SD. Dt were nlyzed using the Kruskl-Wllis test if comprisons involved three groups, nd the Mnn-Whitney U-test nd Spermn's rnk-correltion test if comprisons involved two groups s norml distributions were not obtined. EGFR expression ws split into high- nd low-level groups using recursive descent prtition nlysis, s described by Hoffmnn et l (24). Ctegoricl vribles were compred using the χ 2 test (Fisher's exct probbility test). Survivl curves were constructed using the Kpln-Meier product-limit method nd were compred using the log-rnk test. To evlute independent prognostic fctors ssocited with survivl, multivrite Cox
632 fujit et l: EGFR mrna expression in PDAC Figure 1. Immunohistochemicl nlysis of EGFR in norml pncres, chronic pncretitis nd PDAC tissues. Wek to moderte immunorectivity for EGFR ws detected in some cinr cells nd pncretic ductl cells (A-D). In PDAC tissues, immunorectivity for EGFR ws observed on the surfce nd in the cytoplsm of cncer cells (E-G), with no immunorectivity in the surrounding strom (E-H). The immunorectivity ws different in respective cses (E, strong; F, moderte; G, wek expression; H, bsent). Scle brs represent 200 µm (A, C, E-H) nd 100 µm (B nd D). proportionl hzrds regression nlysis ws used. Sttisticl significnce ws defined s p-vlue of <0.05. Results EGFR protein expression ws correlted with EGFR mrna expression. We performed immunohistochemicl nlyses on 15 sections of non-mlignnt pncretic tissues, including 7 norml, 8 chronic pncretitis tissues nd 25 PDAC tissues. In greement with the findings of previous studies (10,13), wek to moderte immunorectivity for EGFR ws detected in some cinr cells nd pncretic ductl cells (Fig. 1A-D). EGFR immunorectivity ws observed on the surfce nd in the cytoplsm of cncer cells within PDAC tissues, but none ws observed in the surrounding strom (Fig. 1E-G) (10,13). To investigte the correltion between EGFR immunorectivity nd EGFR mrna expression levels within ech FFPE tissue smple from resected PDAC tissue, we evluted the degree of stining (quntity x intensity) for n nti-egfr ntibody, s the immunorectivity ws different in respective cses (Fig. 1E, strong; F, moderte; G, wek expression; nd H, bsent). We found significnt correltion between the degree of stining nd EGFR mrna expression levels [Fig. 2A; Spermn's rnk-correltion coefficient (ρ): 0.729, p<0.0001], nd cses with higher degree of immunorectivity expressed significntly higher levels of EGFR mrna compred with those with lower degree of immunorectivity (Fig. 2B; p=0.0005). These observtions suggest tht quntittive mrna nlysis of EGFR in mcrodissected PDAC tissues my reflect EGFR protein expression levels in EGFR-
INTERNATIONAL JOURNAL OF ONCOLOGY 38: 629-641, 2011 633 Figure 3. Quntittive nlysis of EGFR mrna expression levels in FFPE tissue smples from resected PDAC tissues (n=88) using qrt-pcr. After normliztion to β-ctin expression, we obtined 2 groups with high EGFR expression nd low EGFR expression using cut-off vlue (0.058) determined with recursive descent prtition nlysis, respectively (A). There ws no significnt difference in EGFR mrna levels between the respective groups (non-ac group, n=18; GEM group, n=36; other AC group, n=19; p=0.26) (B). Figure 2. Correltion between EGFR immunorectivity nd EGFR mrna expression levels in ech FFPE tissue smple from resected PDAC tissues (A; n=25). We observed significnt correltion between the degree of stining (quntity x intensity) nd EGFR mrna expression levels [A; Spermn's rnk-correltion coefficient (ρ): 0.729, p<0.0001], nd cses with higher degree of stining (6-9; n=15) expressed significntly higher levels of EGFR mrna compred to cses with lower degree of stining (0-4; n=10) (B; p=0.0005). We found tht EGFR expression levels in the PDAC smples (n=88) were significntly higher thn those in the non-mlignnt smples (n=40) (C; p=0.0004). expressing cncer cells. Additionlly, lthough there ws immunorectivity for EGFR in some cinr nd ductl cells in non-mlignnt cses, we found tht EGFR expression levels in PDAC smples (n=88) were significntly higher thn those in non-mlignnt smples (n=40) (Fig. 2C; p=0.0004). Univrite nd multivrite nlyses of EGFR mrna expression nd survivl time. We quntified EGFR mrna expression levels in FFPE tissue smples from resected PDAC tissues using qrt-pcr. After normliztion to β-ctin, we obtined two groups (high EGFR expression nd low EGFR expression) using cut-off vlue (0.058) determined by recursive descent prtition nlysis of ll ptients (n=88) (Fig. 3A) (24). The high nd low EGFR expression groups comprised of 46 nd 42 cses, respectively. The reltionship between EGFR mrna expression nd the clinicopthologicl fctors seen in PDAC ptients is shown in Tble II. We found no significnt correltion between EGFR mrna expression nd clinicopthologicl fctors. In ddition, there ws no significnt difference in EGFR mrna levels between the non-ac group, the GEM group, nd the other AC group (p=0.26; Fig. 3B). Initilly, we exmined the independent mrkers tht indicted poor prognosis in the 88 PDAC ptients. Univrite nlyses for DFS nd OS (Tble III) showed tht conventionl prognostic mrkers, such s pn sttus (p=0.0009 nd p=0.0026, respectively), residul tumor ctegory (R fctor) (p<0.0001 nd p<0.0001, respectively), nd positive vessel invsion (p=0.0018 nd p=0.0035, respectively) reched sttisticl significnce, wheres the effect of AC did not (p=0.23 nd p=0.066, respectively). High EGFR levels fter normliztion to β-ctin were ssocited with shorter DFS nd OS (Tble III nd Fig. 4A-B; p=0.029 nd p=0.014, respectively). Multivrite nlysis bsed on the Cox proportionl hzrds model ws performed on ll prmeters tht were found to be significnt by univrite nlyses for DFS (Tble IV) nd OS
634 fujit et l: EGFR mrna expression in PDAC Tble II. Reltionship between EGFR mrna expression nd vrious clinicopthologicl fctors. EGFR mrna expression ----------------------------------------------------------------------------------------------- Chrcteristics High-level group (n=46) Low-level group (n=42) P-vlue Age 0.808 65 yers 24 (52.2%) 23 (54.8%) <65 yers 22 (47.8%) 19 (45.2%) Adjuvnt chemotherpy (AC) 0.484 No 8 (17.4%) 10 (23.8%) Yes 33 (71.7%) 22 (52.4%) Gemcitbine-bsed AC 21 (45.7%) 15 (35.7%) Other AC 12 (26.1%) 7 (16.7%) Rdiotherpy 0.368 Yes 10 (21.7%) 13 (30.9%) No 29 (63.0%) 24 (57.1%) pt ctegory 0.543 pt1/pt2 5 (10.9%) 3 (7.1%) pt3/pt4 41 (89.1%) 39 (92.9%) pn ctegory 0.169 pn0 11 (23.9%) 16 (38.1%) pn1 34 (73.9%) 26 (61.9%) UICC stge 0.804 I 3 (6.5%) 3 (7.1%) II 41 (89.1%) 37 (88.1%) III/IV 1 (2.2%) 2 (4.8%) Histologicl grde 0.220 G1 10 (21.7%) 10 (23.8%) G2 14 (30.4%) 19 (45.2%) G3 21 (45.7%) 12 (28.6%) Residul tumor ctegory 0.336 R0 26 (56.5%) 29 (69.0%) R1 18 (39.1%) 13 (30.9%) Vessel invsion 0.256 Positive 31 (67.4%) 24 (57.1%) Negtive 14 (30.4%) 18 (42.9%) Neurl invsion 0.891 Positive 37 (80.4%) 35 (83.3%) Negtive 8 (17.4%) 7 (16.7%) Cut-off vlue (0.058) ws determined by recursive descent prtition nlysis of ll ptients (n=88). (Tble V). DFS ws significntly dependent on the R fctor (p<0.0001) nd vessel invsion (p=0.038), wheres OS ws significntly dependent on the R fctor lone (p<0.0001). The effect of high EGFR levels did not rech sttisticl significnce for either DFS or OS. In order to determine which prmeters were predictive for gemcitbine sensitivity, we then evluted the correltion between ech prmeter nd DFS in the GEM nd non-ac groups. We found no significnt correltion between the level of EGFR mrna expression nd clinicopthologicl fctors in the GEM group (Tble VI). Univrite survivl nlyses of the GEM group showed tht pn sttus (p=0.0094), residul tumor (p=0.0004), nd high EGFR level normlized to β-ctin (Fig. 5A; p=0.068) reched sttisticl significnce for DFS (Tble VII). However, there ws no significnt correltion between the EGFR expression level nd DFS in the non-ac group (p=0.30, Fig. 5C), lthough the number of ptients who did not receive AC ws limited. Multivrite nlysis of the GEM group (Tble VIII) showed tht DFS ws significntly dependent on both the R fctor (p=0.0071) nd high EGFR levels (p=0.010). Similrly, we evluted the correltion between ech prmeter nd OS in the GEM nd non-ac groups. Univrite survivl nlyses of the GEM group showed tht the conventionl prognostic mrkers, pn sttus (p=0.020), R fctor (p=0.013), nd high EGFR levels normlized to β-ctin (Fig. 5B; p=0.054) reched sttisticl significnce for OS (Tble VII). However, the effect of EGFR expression levels
INTERNATIONAL JOURNAL OF ONCOLOGY 38: 629-641, 2011 635 Tble III. Univrite survivl nlysis of conventionl prognostic fctors nd EGFR mrna expression (n=88). Chrcteristics Number of Medin DFS P-vlue Medin OS P-vlue 5-yer survivl cses (months) (months) rte EGFR mrna expression 0.029 b 0.014 b High 42 7.0 14.6 19.9% Low 46 25.0 35.5 37.9% Age 0.96 0.93 65 yers 47 12.0 26.0 24.6% <65 yers 41 8.0 19.0 35.4% Adjuvnt chemotherpy (AC) 0.23 0.066 Yes 64 12.0 23.0 33.4% No 20 7.0 12.1 14.3% Rdiotherpy 0.77 0.58 Yes 23 12.0 23.0 29.5% No 53 10.0 20.0 22.4% pt ctegory 0.34 0.54 pt1/pt2 8 22.0 63.0 62.5% pt3/pt4 80 8.0 23.0 25.5% pn ctegory 0.0009 b 0.0026 b pn0 27 36.0 45.0 49.3% pn1 60 8.0 16.3 19.0% UICC stge 0.14 0.28 I 6 26.5 63.0 83.3% II 78 8.0 20.9 25.3% III/IV 3 16.0 19.8 0% Histologicl grde 0.072 0.16 G1/G2 54 14.0 30.0 31.9% G3 33 8.0 14.6 27.4% Residul tumor ctegory <0.001 b <0.001 b R0 55 26.0 43.0 43.4% R1 31 5.0 12.0 5.3% Vessel invsion 0.0018 b 0.0035 b Positive 55 7.0 16.9 18.7% Negtive 32 31.0 45.0 45.0% Neurl invsion 0.95 0.76 Positive 72 10.0 23.0 26.0% Negtive 15 14.0 19.0 24.3% Cut-off vlue (0.058) ws determined by recursive descent prtition nlysis of ll ptients (n=88); b p<0.05. Tble IV. Multivrite DFS nlysis (Cox regression model) of conventionl prognostic fctors nd EGFR mrna. Chrcteristics Reltive risk 95% Confidence intervl P-vlue High EGFR levels 1.208 0.680-2.192 0.523 pn ctegory (pn1) 1.939 0.966-4.166 0.063 Residul tumor ctegory (pr1) 4.957 2.647-9.281 <0.0001 b Positive vessel invsion 1.942 1.036-3.825 0.038 b Cut-off vlue (0.058) ws determined by recursive descent prtition nlysis of ll ptients (n=88); b p<0.05.
636 fujit et l: EGFR mrna expression in PDAC Figure 4. DFS nd OS fter resection of PDAC with high versus low EGFR expression. High EGFR mrna levels were ssocited with shorter DFS (A, p=0.029) nd shorter OS (B, p=0.014). * p<0.05. did not rech significnce in the non-ac group (p=0.07, Fig. 5D). Multivrite nlysis of the GEM group (Tble IX) showed tht OS ws significntly dependent on pn sttus (p=0.024), R fctor (p=0.045), nd high EGFR levels (p=0.023). These dt suggest tht high EGFR expression is significnt predictor for reduced DFS nd significnt prognostic indictor for reduced OS, especilly in those ptients receiving gemcitbine-bsed AC. Quntittive nlysis of EGFR expression in cells microdissected from cytologicl specimens. In order to pply this prediction of outcome for PDAC ptients receiving gemcitbinebsed chemotherpy bsed on EGFR expression levels to clinicl setting, we quntified the EGFR mrna levels in cytologicl specimens obtined from 20 ptients with PDAC who underwent EUS-FNA cytologicl exmintion t our institute. Although some smples contined bundnt Figure 5. DFS nd OS fter resection of PDAC with high versus low EGFR expression in the GEM (A nd B; n=36) nd non-ac (C nd D; n=18) groups. High EGFR mrna levels were ssocited with shorter DFS (A, p=0.068) nd shorter OS (B, p=0.054) in the GEM group. In contrst, there ws no significnt correltion between EGFR expression levels nd DFS (C, p=0.30) or OS (D, p=0.07) in the non-ac group. * p<0.05. neoplstic cells, most smples contined lrge mount of blood nd inflmmtory cells nd scrce clusters of neoplstic cells (Fig. 6A-B). Therefore, we quntified the EGFR mrna levels in the WCP nd LCM smples, nd then compred the expression levels between the two. We were unble to detect cler differences in EGFR mrna levels in the WCP smples. However, we distinguished higher nd lower expression levels of the mrna in the LCM smples (Fig. 6C). These dt suggest tht the quntifiction of EGFR expression levels in microdissected neoplstic cells could be potent tool for Tble V. Multivrite OS nlysis (Cox regression model) of conventionl prognostic fctors nd EGFR mrna. Chrcteristics Reltive risk 95% Confidence intervl P-vlue High EGFR levels (>0.058) 1.649 0.958-2.873 0.071 pn ctegory (pn1) 1.671 0.888-3.350 0.114 Residul tumor ctegory (pr1) 3.059 1.762-5.324 <0.0001 b Positive vessel invsion 1.784 0.979-3.416 0.059 Cut-off vlue (0.058) ws determined by recursive descent prtition nlysis of ll ptients (n=88); b p<0.05.
INTERNATIONAL JOURNAL OF ONCOLOGY 38: 629-641, 2011 637 Tble VI. Reltionship between EGFR mrna expression nd vrious clinicopthologicl fctors in the GEM group (n=36). EGFR mrna expression ----------------------------------------------------------------------------------------------- Chrcteristics High-level group (n=46) Low-level group (n=42) P-vlue Age 0.176 65 yers 11 (52.4%) 4 (26.7%) <65 yers 10 (47.6%) 11 (73.3%) Gender 0.736 Mle 14 (66.7%) 9 (60.0%) Femle 7 (33.3%) 6 (40.0%) Rdiotherpy 0.084 Yes 2 (9.5%) 5 (33.3%) No 18 (90.5%) 8 (66.7%) pt ctegory 1.000 pt1/pt2 1 (4.8%) 0 (0%) pt3/pt4 20 (95.2%) 15 (100%) pn ctegory 0.694 pn0 4 (19.0%) 4 (26.7%) pn1 17 (81.0%) 11 (73.3%) UICC stge 1.000 I - - II 20 (95.2%) 14 (93.3%) III/IV 1 (4.8%) 1 (6.7%) Histologicl grde 0.297 G1 4 (19.0%) 3 (20.0%) G2 5 (23.8%) 7 (46.7%) G3 12 (57.2%) 5 (33.3%) Residul tumor ctegory 0.282 R0 12 (57.2%) 12 (80.0%) R1 9 (4.8%) 3 (20.0%) Vessel invsion 0.499 Positive 15 (71.4%) 9 (60.0%) Negtive 6 (28.6%) 6 (40.0%) Neurl invsion 1.000 Positive 17 (81.0%) 13 (86.7%) Negtive 4 (19.0%) 2 (13.3%) Cut-off vlue (0.058) ws determined by recursive descent prtition nlysis of ll ptients (n=88) nd the GEM group (n=36). predicting the outcome of PDAC ptients, even when specimens contin bundnt contminted cells. Discussion There is incresing evidence showing the usefulness of immunohistochemicl nlysis of moleculr mrkers, including EGFR, for predicting the clinicl outcome of PDAC ptients (10,11,13,25,26). Immunohistochemicl nlysis is vlid method s it shows protein expression. However, the clinicl introduction of immunohistochemicl ssessment for predicting sensitivity to chemotherpeutic gents is still problemtic due to difficulties in quntittive mesurement (inter-observer vritions in interprettion) nd the lck of clibrted quntifiction techniques (27-29). In ddition, only 10-20% of ptients with PDAC re cndidtes for curtive resection (3). Therefore, the remining 80 90% of ptients with dvnced PDAC need cytopthologicl ssessment with EUS-FNA, or pncretic juice, to predict their sensitivity to chemotherpeutic gents for individulized chemotherpy. The present nlysis of EGFR mrna is quntittive (even considering the smll mount of specimens vilble, including cytologicl specimens). For these resons, quntittive mrna nlysis of genes ssocited with tumor sensitivity, or with resistnce to nti-tumor gents, could be preferred to immunohistochemicl nlysis in clinicl setting. Furthermore, we introduced the use of LCM to obtin trget cells from EUS-FNA cytologicl specimens (17). As result, we found tht EGFR mrna levels in microdissected neoplstic cells were esier to distinguish thn those in WCP, suggesting tht quntifiction of the expression levels of individul genes in microdissected neoplstic cells could be potent tool for
638 fujit et l: EGFR mrna expression in PDAC Tble VII. Univrite survivl nlysis of conventionl prognostic fctors nd EGFR mrna expression in the GEM group (n=36). Chrcteristics Number of Medin DFS P-vlue Medin OS P-vlue 5-yer survivl cses (months) (months) rte EGFR mrna expression 0.0068 b 0.0054 b High 42 7 14.6 8.2% Low 46 25 45.0 46.0% Age 0.57 0.92 65 yers 17 8 27.0 24.8% <65 yers 23 10 23.0 26.8% Gender 0.45 0.71 Mle 26 14 27.0 20.9% Femle 14 6 13.7 27.7% Rdiotherpy 0.32 0.24 Yes 9 12 27.0 34.3% No 27 8 19.0 12.1% pt ctegory 0.25 0.09 pt1/pt2 1 4 10.0 0.0% pt3/pt4 39 10 26.0 26.1% pn ctegory 0.0094 b 0.020 b pn0 9 45.0 46.7% pn1 31 8 19.0 19.0% UICC stge 0.62 0.35 I 0 - - - II 37 8 23.0 27.4% III/IV 3 2 19.0 0.0% Histologicl grde 0.086 0.071 G1/G2 23 14 31.0 33.3% G3 17 8 19.0 13.9% Residul tumor ctegory 0.0004 b 0.013 b R0 26 19 30.2 39.6% R1 14 5 13.7 0.0% Vessel invsion 0.079 0.26 Positive 26 8 23.0 23.6% Negtive 14 25 31.0 29.2% Neurl invsion 0.56 0.84 Positive 33 9 26.0 23.5% Negtive 7 8 15.6 50.0% Cut-off vlue (0.058) ws determined by recursive descent prtition nlysis of ll ptients (n=88) nd the GEM group (n=36); b p<0.05. Tble VIII. Multivrite DFS nlysis (Cox regression model) of conventionl prognostic fctors nd EGFR mrna expression levels in the GEM group (n=36). Chrcteristics Reltive risk 95% Confidence intervl P-vlue pn sttus (pn1) 2.654 0.892-11.41 0.083 Residul tumor ctegory (pr1) 3.197 1.383-7.365 0.0071 b High EGFR levels (>0.058) 3.016 1.292-7.742 0.010 b Cut-off vlue (0.058) ws determined by recursive descent prtition nlysis of ll ptients (n=88) nd the GEM group (n=36); b p<0.05.
INTERNATIONAL JOURNAL OF ONCOLOGY 38: 629-641, 2011 639 Tble IX. Multivrite OS nlysis (Cox regression model) of conventionl prognostic fctors nd EGFR mrna expression levels in the GEM group (n=36). Chrcteristics Reltive risk 95% Confidence intervl P-vlue pn sttus (pn1) 3.451 1.157-14.89 0.024 b Residul tumor ctegory (pr1) 2.442 1.021-5.858 0.045 b High EGFR levels (>0.058) 2.882 1.154-8.194 0.023 b Cut-off vlue (0.058) ws determined by recursive descent prtition nlysis of ll ptients (n=88) nd the GEM group (n=36); b p<0.05. Figure 6. Quntittive nlyses of EGFR mrna in EUS-FNA cytologicl specimens. Representtive microgrphs of cytologicl specimens obtined from ptients with PDAC who underwent EUS-FNA cytologicl exmintion (A nd B). Most smples contined lrge mount of blood nd inflmmtory cells with scrce clusters of neoplstic cells. (C) Quntittive nlysis of EGFR in EUS-FNA cytologicl specimens (n=20). Although we did not detect cler chnges in expression levels in the WCP smples, we distinguished smples hving higher nd lower EGFR expression levels in the microdissected neoplstic cells (C). predicting sensitivity to nti-tumor gents, even when specimens contin contminted cells. However, further investigtions, including prospective studies, re required before this pproch cn be introduced into the clinicl setting. As EGFR plys crucil role in controlling the ctivity of the Rs/MAPK signling pthwy (8,9), gret efforts hve been mde to develop strtegies trgeting EGFR (30). In xenogrft models of pncretic cncer, the combintion of gemcitbine nd EGFR-trgeted therpy significntly inhibited lymph node nd liver metstses nd improved OS (16). A rndomized, plcebo-controlled phse III tril compring erlotinib, n EGFR tyrosine kinse inhibitor (TKI), plus gemcitbine to gemcitbine lone in ptients with loclly dvnced or metsttic pncretic cncer, demonstrted tht
640 fujit et l: EGFR mrna expression in PDAC the combintion of erlotinib nd gemcitbine provided smll, yet sttisticlly significnt survivl benefit (31). However, the efficcy of EGFR TKI in pncretic cncer trils hs not met expecttions, not s it hs in proportion of ptients with non-smll cell lung cncer (NSCLC) (30). This is likely due to differences in the presence of ctivting muttions within EGFR, which re ssocited with prolonged responses in NSCLC (32). Mny studies hve identified ctivting EGFR gene muttions in only smll number of cses in PDAC ptients (33,34). However, Tn et l demonstrted tht higher genetic mplifiction of the EGFR region of chromosome 7 is ssocited with better clinicl responses to erlotinib tretment in dvnced NSCLC ptients (35). Therefore, there is possibility tht quntittive nlysis of EGFR mrna expression levels could be helpful in predicting sensitivity to erlotinib in PDAC ptients. However, further investigtions incorporting lrger ptient numbers re required to evlute the usefulness of this pproch. In conclusion, we demonstrte tht quntittive nlysis of EGFR mrna expression using FFPE tissue smples is useful for predicting the prognosis of PDAC ptients receiving gemcitbine-bsed AC. In ddition, quntittive nlysis of EGFR mrna in neoplstic cells microdissected from EUS-FNA specimens is useful for determining tretment for ptients with PDAC, even when the tumor is unresectble. Thus, quntittive nlysis of genes ssocited with sensitivity to cytotoxic gents could be potent tool for individulized chemotherpy. Acknowledgements We would like to thnk Mr. F. Ohkubo (Deprtment of Pthology, Kyushu University Hospitl) for skillful cytologicl exmintion nd nlysis. We lso thnk Ms. S. Sdtomi, Ms. M. Sto, Ms M. Ohmori nd Ms. E. Mnbe (Deprtment of Surgery nd Oncology, Kyushu University Hospitl) for skillful exmintion nd nlysis. This study ws supported, in prt, by the following grnts: A grnt (H20-Nnchi- Ippn-027) from the Ministry of Helth, Lbour nd Welfre, Jpn, Grnt-in-Aid from the Ministry of Eduction, Culture, Sports, Science nd Technology of Jpn, nd grnts from the Jpnese Society of Gstroenterology nd the Pncretic Reserch Foundtion of Jpn. H.F. is recipient of Scientific Reserch Fellowship from the Assocition for Preventive Medicine of Jpn. References 1. Hirt K, Egw S, Kimur Y, et l: Current sttus of surgery for pncretic cncer. Dig Surg 24: 137-147, 2007. 2. Jeml A, Siegel R, Wrd E, Ho Y, Xu J nd Thun MJ: Cncer sttistics, 2009. CA Cncer J Clin 59: 225-249, 2009. 3. Mtsuno S, Egw S, Fukuym S, et l: Pncretic Cncer Registry in Jpn: 20 yers of experience. Pncres 28: 219-230, 2004. 4. Crpeln-Holmstrom M, Nordling S, Pukkl E, et l: Does nyone survive pncretic ductl denocrcinom? A ntionwide study re-evluting the dt of the Finnish Cncer Registry. Gut 54: 385-387, 2005. 5. Wgner M, Redelli C, Lietz M, Seiler CA, Friess H nd Buchler MW: Curtive resection is the single most importnt fctor determining outcome in ptients with pncretic denocrcinom. Br J Surg 91: 586-594, 2004. 6. Neoptolemos JP, Stocken DD, Friess H, et l: A rndomized tril of chemordiotherpy nd chemotherpy fter resection of pncretic cncer. N Engl J Med 350: 1200-1210, 2004. 7. Oettle H, Post S, Neuhus P, et l: Adjuvnt chemotherpy with gemcitbine vs observtion in ptients undergoing curtiveintent resection of pncretic cncer: rndomized controlled tril. JAMA 297: 267-277, 2007. 8. Lemoine NR, Hughes CM, Brton CM, et l: The epiderml growth fctor receptor in humn pncretic cncer. J Pthol 166: 7-12, 1992. 9. Xiong HQ: Moleculr trgeting therpy for pncretic cncer. Cncer Chemother Phrmcol 54 (Suppl 1): 69-77, 2004. 10. Dong M, Nio Y, Guo KJ, Tmur K, Tin YL nd Dong YT: Epiderml growth fctor nd its receptor s prognostic indictors in Chinese ptients with pncretic cncer. Anticncer Res 18: 4613-4619, 1998. 11. Tobit K, Kijim H, Dowki S, et l: Epiderml growth fctor receptor expression in humn pncretic cncer: Significnce for liver metstsis. Int J Mol Med 11: 305-309, 2003. 12. Ued S, Ogt S, Tsud H, et l: The correltion between cytoplsmic overexpression of epiderml growth fctor receptor nd tumor ggressiveness: poor prognosis in ptients with pncretic ductl denocrcinom. Pncres 29: e1-e8, 2004. 13. Ymnk Y, Friess H, Kobrin MS, Buchler M, Beger HG nd Korc M: Coexpression of epiderml growth fctor receptor nd lignds in humn pncretic cncer is ssocited with enhnced tumor ggressiveness. Anticncer Res 13: 565-569, 1993. 14. Lurje G nd Lenz HJ: EGFR signling nd drug discovery. Oncology 77: 400-410, 2009. 15. Bruns CJ, Solorzno CC, Hrbison MT, et l: Blockde of the epiderml growth fctor receptor signling by novel tyrosine kinse inhibitor leds to poptosis of endothelil cells nd therpy of humn pncretic crcinom. Cncer Res 60: 2926-2935, 2000. 16. Ng SS, Tso MS, Nicklee T nd Hedley DW: Effects of the epiderml growth fctor receptor inhibitor OSI-774, Trcev, on downstrem signling pthwys nd poptosis in humn pncretic denocrcinom. Mol Cncer Ther 1: 777-783, 2002. 17. Fujit H, Ohuchid K, Mizumoto K, et l: Quntittive nlysis of htert mrna levels in cells microdissected from cytologicl specimens. Cncer Sci 99: 2244-2251, 2008. 18. Sobin LH: TNM, sixth edition: new developments in generl concepts nd rules. Semin Surg Oncol 21: 19-22, 2003. 19. Nkt K, Ohuchid K, Ngi E, et l: LMO2 is novel predictive mrker for better prognosis in pncretic cncer. Neoplsi 11: 712-719, 2009. 20. Chomczynski P nd Scchi N: Single-step method of RNA isoltion by cid gunidinium thiocynte-phenol-chloroform extrction. Anl Biochem 162: 156-159, 1987. 21. Ohuchid K, Mizumoto K, Ogur Y, et l: Quntittive ssessment of telomerse ctivity nd humn telomerse reverse trnscriptse messenger RNA levels in pncretic juice smples for the dignosis of pncretic cncer. Clin Cncer Res 11: 2285-2292, 2005. 22. Abrhmsen HN, Steiniche T, Nexo E, Hmilton-Dutoit SJ nd Sorensen BS: Towrds quntittive mrna nlysis in prffinembedded tissues using rel-time reverse trnscriptse- polymerse chin rection: methodologicl study on lymph nodes from melnom ptients. J Mol Dign 5: 34-41, 2003. 23. Antonov J, Goldstein DR, Oberli A, et l: Relible gene expression mesurements from degrded RNA by quntittive rel-time PCR depend on short mplicons nd proper normliztion. Lb Invest 85: 1040-1050, 2005. 24. Hoffmnn AC, Mori R, Vllbohmer D, et l: High expression of HIF1 is predictor of clinicl outcome in ptients with pncretic ductl denocrcinoms nd correlted to PDGFA, VEGF, nd bfgf. Neoplsi 10: 674-679, 2008. 25. Grce G, Nel CP, Pttenden CJ, Stewrd WP nd Berry DP: Moleculr prognostic mrkers in pncretic cncer: systemtic review. Eur J Cncer 41: 2213-2236, 2005. 26. Ghneh P, Kwesh A, Evns JD nd Neoptolemos JP: Moleculr prognostic mrkers in pncretic cncer. J Heptobiliry Pncret Surg 9: 1-11, 2002. 27. Koutrs AK, Klogers KT, Dimopoulos MA, et l: Evlution of the prognostic nd predictive vlue of HER fmily mrna expression in high-risk erly brest cncer: Hellenic Coopertive Oncology Group (HeCOG) study. Br J Cncer 99: 1775-1785, 2008. 28. O'Lery TJ: Stndrdiztion in immunohistochemistry. Appl Immunohistochem Mol Morphol 9: 3-8, 2001.
INTERNATIONAL JOURNAL OF ONCOLOGY 38: 629-641, 2011 641 29. Pik S, Brynt J, Tn-Chiu E, et l: Rel-world performnce of HER2 testing-ntionl Surgicl Adjuvnt Brest nd Bowel Project experience. J Ntl Cncer Inst 94: 852-854, 2002. 30. Fller BA nd Burtness B: Tretment of pncretic cncer with epiderml growth fctor receptor-trgeted therpy. Biologics 3: 419-428, 2009. 31. Moore MJ, Goldstein D, Hmm J, et l: Erlotinib plus gemcitbine compred with gemcitbine lone in ptients with dvnced pncretic cncer: phse III tril of the Ntionl Cncer Institute of Cnd Clinicl Trils Group. J Clin Oncol 25: 1960-1966, 2007. 32. Sequist LV, Mrtins RG, Spigel D, et l: First-line gefitinib in ptients with dvnced non-smll-cell lung cncer hrboring somtic EGFR muttions. J Clin Oncol 26: 2442-2449, 2008. 33. Kwk EL, Jnkowski J, Thyer SP, et l: Epiderml growth fctor receptor kinse domin muttions in esophgel nd pncretic denocrcinoms. Clin Cncer Res 12: 4283-4287, 2006. 34. Tzeng CW, Frolov A, Frolov N, et l: Epiderml growth fctor receptor (EGFR) is highly conserved in pncretic cncer. Surgery 141: 464-469, 2007. 35. Tn EH, Rmlu R, Pluznsk A, et l: A multicentre phse II gene expression profiling study of puttive reltionships between tumour biomrkers nd clinicl response with erlotinib in non-smll-cell lung cncer. Ann Oncol 21: 217-222, 2010.